Precigen Email Format
Biotechnology ResearchMaryland, United States51-200 Employees
Precigen is a commercial-stage biotechnology company focused on precision medicines to address difficult-to-treat diseases with high unmet patient need. It aims to advance scientific breakthroughs from proof-of-concept to commercialization, building a pipeline of differentiated therapies across immuno-oncology, autoimmune disorders, and infectious diseases. The company is headquartered in Germantown, Maryland, and operates within the biotechnology research sector. Precigen trades on Nasdaq under the ticker PGEN. In 2026, the FDA granted orphan drug exclusivity for PAPZIMEOS for adults with recurrent respiratory papillomatosis, providing seven years of market protection. That year also saw disclosure of long-term durability data for PAPZIMEOS, reflecting ongoing progress with the therapy in its pivotal study.